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Summary. Introduction: T1 bladder cancer is associated with a high risk of recurrence and progression; con-
comitant carcinoma in situ and/or multifocality are negative prognostic factors. Persistent disease after re-
section of T1 tumours has been observed in 33-55% of patients, and after resection of High-grade (HG) 
Ta tumour in 41,4%. It has been demonstrated that a second TURB can increase recurrence-free survival 
and it can make a restaging of the cancer. Patients and methods: From January 2011 to December 2016, 87 
patients with superficial bladder tumor (Ta-T1), undergoing TURB and routine repeat TURB (Re-TURB) 
4-6 weeks after the initial resection, were included in the study. Re-TURB was applied to the scar of the first 
resection and other suspicious lesions in the bladder. After the second-look, we studied the follow-up of each 
patient. Results: Specimens obtained during the second TURBT showed no tumor in 47 (54,02%) patients; 
40 (45,98%) patients had residual cancer: 34 of them had cancer of the same stage, 6 patients of pT1 had a 
lower stage, and 3 had a higher stage. 5 patient underwent radical cistectomy immediatly after re-TURBT. 
During the first year of follow up, 15 patients had a recurrent bladder cancer; 2 of them underwent radical 
cistectomy. Conclusions: T1 bladder cancer is an high risk tumor, so that second-look TURBT is a valuable 
procedure for accurate staging of nonmuscle-invasive bladder cancer and it can guarantee a better eradication 
of the neoplasm. (www.actabiomedica.it)
Key words: second-look TURBT, Re-TURBT, bladder cancer, NMIBC, cistectomy
Acta Biomed 2020; Vol. 91, N. 2: 322-325 DOI: 10.23750/abm.v91i2.8618  © Mattioli 1885
O r i g i n a l  a r t i c l e
Introduction
Stage Ta and T1 bladder tumors are defined as 
non-muscle-invasive bladder cancers: they are con-
fined to the mucosa or invade the lamina propria re-
spectively. These low stage and grade tumors are ex-
pected to be non metastatic neoplasm according to 
the Tumour, Node, Metastasis (TNM) classification 
system. In spite of that, high-grade (HG) Ta and T1 
tumors are associated with high risk of recurrence and 
progression, especially when present concomitant car-
cinoma in situ (CIS) and/or are multifocal (1). The 
invasion of bladder detrusor changes the prognosis 
and requires a radical treatment often rappresented by 
radical cistectomy.
Guidelines on non-muscle-invasive bladder can-
cer of the European Association of Urology (EAU) state 
that it is possible to find residual disease after the first 
bladder resection (TURBT) in 33-55% of patients 
with T1 tumours and in 41,4% of patients with TaHG 
(2-3). Based on these arguments, a second TURBT is 
recommended in selected cases (4): 
•  after incomplete initial TURBT;
•  if there is no muscle in the specimen after initial 
resection, with the exception of  low-grade (LG) 
Ta tumours and primary CIS;
Second-look TURBT: evaluation of results in a single center 323
• in all T1 tumours;
• in all HG tumours, except primary CIS.
The aim of our study is proving the necessity of 
the second-look TURBT according to the data col-
lected in the department of Urology of G. Salvini 
Hospital. 
Patients and methods
We recruited all patients who underwent a 
TURBT from January 2011 to December 2016 in 
G. Salvini Hospital of Garbagnate Milanese. We ob-
tained 966 TURBT, executed in 705 patients. 87 of 
them underwent a re-TURBT (Table 1). For each pa-
tient, we analyzed the pathological report, with par-
ticular attention to morphology (localization, number 
and diameter of tumours, concurrent CIS, presence of 
muscle in the specimen, prior recurrence rate), stage T 
and grade G of the tumours. We calculated the risk of 
recurrence and progression according to the EORTC 
tables (European Organization for Research and Treat-
ment of Cancer) (5). 
According to the EAU guidelines we performed 
the re-TURBT at 6-8 weeks from the first bladder re-
section (6). When the pathological result of the sec-
ond resection presented residual disease we planned, 
based on the stage and grade obtained, a conservative 
approach with bladder instillation in some cases (BCG 
or Mitomicin C) or a surgical approach with radical 
cistectomy in other patients.
Our follow-up after the re-TURBT consists of: 
cistoscopy and urinary cytology at 3 months. If nega-
tive, cystoscopy and cytology every 3 months for a pe-
riod of 2 years, and every 6 months thereafter until 5 
years, and then yearly, according to EAU giudelines. 
Results
First-look results
We selected 87 patients who underwent a re-
TURBT (70 men and 17 women). In Tables 2, 3, and 4 
are reported pathological results after the first bladder 
resection. Table 5 shows the pathological indications 
to the second resection.
Second-look results
Specimens obtained during the second TURBT 
showed no tumor in 47 (54,02%) patients; 40 (45,98%) 
patients had residual cancer: 34 of them in the same 
stage, 6 patients with previous pT1 presented a lower 
stage (pTa), and 3 had a higher stage (pT2).
50% of patients presenting no detrusor in the first 
specimen had residual tumor at the re-TURBT; in Ta-
ble 6 are reported the pathological results.
Table 1. Population characteristics
Patients 
Number of TURBT 966
Male 552
Female 153
Age (mean ± DS) 74 ± 8,87
Range 58 - 88
Number of second TURBT 87




No bladder muscle 16 (18,3%)
Table 3. T1LG tumours with detrusor in the specimen
T1G1 tumours 
Number of tumours Single = 9
 2-7 = 11
 ≥ 8 = 0
Tumour diameter < 3 cm = 11
 ≥ 3 cm = 9 (all single)
Concurrent CIS 0
Table 4. T1G3 tumours with detrusor int the specimen
T1G3 tumours 
Number of tumours Single = 28
 2-7 = 23
 ≥ 8 = 0
Tumour diameter  < 3 cm = 45
 ≥ 3cm = 6
Concurrent CIS 0
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Oncological results
Immediately after re-TURBT, 5 patients, who 
have at first-look a T1HG, underwent radical cistec-
tomy: histological report show T4 bladder cancers. 
These patients still have a good quality of life and good 
health condition. 
We found 15 tumor relapses at a mean follow-up 
time of 261 days. In two cases the tumor resulted pT2 
after the first resection, confirmed at the re-TURBT; 
definitive pathological result after radical cistectomy 
showed a pT4 tumor. The follow-up of these patients 
was studied at 6 and 12 months after radical cystecto-
my with thoracic and abdominal TC, urinary cytology 
and blood tests of kidney function. None of them had 
a relapse of the pathology.
Discussion
The second-look transurethral resection of the 
bladder (re-TURBT) represents a fundamental step in 
the treatment of papillary non-muscle invasive blad-
der cancer (NMIBC) and it is recommended by all 
guidelines. However, not all the literature agrees on 
its staging value and its ability to improve oncological 
outcomes of patients, and it is a surgical procedure not 
free of risks and complications and with an important 
impact on patients’ quality of life, waiting lists and 
healthcare costs.  
Guidelines on non-muscle-invasive bladder can-
cer of the European Association of Urology (EAU) state 
that it is possible to find residual disease after the first 
bladder resection (TURBT) in 33-55% of patients 
with T1 tumors and in 41,4% of patients with TaHG. 
Medical literature gives us some examples: Dr. Aydin 
demonstrates that in the 40% of 100 patients, recruited 
from January 2003 to December 2008, is possible to 
find a neoplasm at second-look (7). 
Our results are comparable to the data reported in 
literature regarding second-look TURBT.
The evidence of residual tumor in 45.98% of sec-
ond resections underlines the importance of this pro-
cedure in order to obtain a complete eradication of 
the cancer despite his biological and economical costs. 
The high percentage (9,19%) of pT1 tumors undergo-
ing radical cistectomy gives a strong role to the re-
TURBT in characterizing and treating an high-risk 
neoplasm. 
We can state that re-TURBT is an important 
procedure in restaging: 6 patients with pT1 had a 
lower stage at second-look, and 3 had a higher stage. 
The efficacy of second TURBT in restaging is limited 
to the distinction between non-muscle-invasive and 
muscle-invasive tumors. 
Based on our results, second-look TURBT maxi-
mizes staging accuracy, allows to clear residual cancer 
and yields prognostic advantages allowing key infor-
mation to identify possible candidates for immediate 
radical cystectomy. The use of re-TURBT let us to 
promptly treat that half of patients with a residual tu-
mor, improving their oncological outcomes. An early 
resection of residual cancer reduce the risk of progres-
sion of the pathology and in the long period can re-
duce the number radical approach. Morover, a prompt 
radical cystectomy can reduce the risk of metastasis.
T1HG tumors are associated with high risk of re-
currence and progression. The 15 tumor relapses, that 
we found, were arisen in patients who had at first re-
section a T1HG neoplasm. Relapses were staged or as 
T1 or as T2. The high number of new bladder tumor 
after second-look TURBT (17,24% of patients at the 
first year of follow-up) prove that these superficial ne-
oplasms are aggressive, and underline the importance 
Table 5. Indications to re-TURBT
Indications to second-look TURBT: 
T1G1 (multiple or notable diameter) 20 (22,98%)
T1G3 51 (58,63%)
No muscle
 16 (18,39%) → 8 T1LG
  → 8 T1HG
Table 6. Pathological results of the re-TURBT
At second-look TURBT: 
No cancer 47 (54,02%)
TaLG   6 (6,89%)
T1LG 14 (16,09%)
T1HG 17 (19,54%)
T2HG   3 (3,46%)
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of an accurate follow-up so that the urologist can re-
moves relapses in order to prevent a progression.
Besides, the high number of radical cistectomy 
(9,19% of patients) proves the tendency to progression 
of T1 tumors. All tumors of these patients were staged 
as T4 at the anatomopathological exam of the bladder. 
This fact further underlines the capability of bladder 
neoplasm to invade progressively the external habit 
of the viscus. Although we found in all cistectomized 
patients a T4 neoplasm, we can’t say that all T1HG 
tumors has the capability to became a T4, because our 
case record is too small to prove that. 
Although our results are similar to the ones re-
ported in literature, this study has some weak points. 
First, it is a single-center study; second, we enrolled a 
small population of patients. A large number of pa-
tients should be required to confirm our results and 
maybe a multicenter study should have a greater sta-
tistical value.
Conclusion 
Based on the data we obtained and on the high 
risk of recurrence and progression of T1 tumours, we 
can state that second-look TURBT is an important 
instrument in the treatment of superficial bladder tu-
mors, because it maximizes staging accuracy, allows a 
total eradication of the neoplasm and yields prognostic 
advantages allowing key information to identify pos-
sible candidates for immediate radical cystectomy, in 
spite of the biological and economical cost of the sec-
ond resection. Therefore, it’s necessary to identify some 
criteria that may better allow to identify patients that 
should be undergone a second-look TURB,  in order 
to avoid an unnecessary intervention linked to possible 
risks and associated with high healthcare costs. 
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